Autoimmune Disease Treatment Market Size, Share, Growth, Outlook, Opportunities and Forecast 2017-2025
According to a recently published report by Brisk Insight, the Global Autoimmune Diseases Treatment Market is expected to grow at the CAGR of 3.8% during 2017-2025. The global autoimmune diseases treatment market is segmented on the basis of therapeutics and geography. The report on global autoimmune diseases treatment market (by therapeutics and geography) provides a detailed overview and predictive analysis of the market.
Full report available Autoimmune Diseases Treatment Market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/autoimmune-disease-treatment-market
Market Insights
Autoimmune disease is defined as functional instability caused to immune system. This reaction takes place when an individual’s immune system defends itself by producing its autoantibodies against the healthy cells and tissues rather than infectious agents. Autoantibodies produced, cause pain, inflammation and sometimes even organ damage. It is one of the top 10 leading causes of mortality in girls and women observed in all age groups up to 64 years of age. Traditionally available treatment options are chemical based drugs which including corticosteroids, immunosuppressants and NSAIDs. In recent development biological drugs are looked are preferred over chemical based drugs , due to less side-effects, target-specific activity and high patient compliance compared to chemical-based drugs. With rising awareness about autoimmune disease, increase in healthcare expenditure in both developed and developing countries are some the driving factors for the growth of autoimmune diseases treatment.
Scope of the report
1. Global Autoimmune Diseases Treatment Market, By Therapeutics Type, 2015–2025 ($ Million)
1.1. Overview
1.2. Chemical-based Drugs
1.2.1. Immunosuppressant Drugs
1.2.2. NSAIDs
1.2.3. Corticosteroids
1.3. Biological Drugs
1.4. Pipeline Analysis
1.4.1. Projected sales of Phase III Drugs estimated till 2025, by Most Prevalent Autoimmune Diseases ($ Million)
1.4.1.1. Hashimoto's Thyroiditis
1.4.1.2. Type I Diabetes
1.4.1.3. Crohn's Disease
1.4.1.4. Multiple Sclerosis
1.4.1.5. Rheumatoid Arthritis
1.4.1.6. Ankylosing Spondylitis
1.4.1.7. Systemic Lupus Erythematosus
1.4.1.8. Psoriasis
1.4.2. Tabular Representation of Phase II and I Drugs
1.2. Chemical-based Drugs
1.2.1. Immunosuppressant Drugs
1.2.2. NSAIDs
1.2.3. Corticosteroids
1.3. Biological Drugs
1.4. Pipeline Analysis
1.4.1. Projected sales of Phase III Drugs estimated till 2025, by Most Prevalent Autoimmune Diseases ($ Million)
1.4.1.1. Hashimoto's Thyroiditis
1.4.1.2. Type I Diabetes
1.4.1.3. Crohn's Disease
1.4.1.4. Multiple Sclerosis
1.4.1.5. Rheumatoid Arthritis
1.4.1.6. Ankylosing Spondylitis
1.4.1.7. Systemic Lupus Erythematosus
1.4.1.8. Psoriasis
1.4.2. Tabular Representation of Phase II and I Drugs
2. Global Autoimmune Diseases Treatment Market, By Geography, 2015-2025 ($ Million)
2.1. North America (U.S. & Canada)
2.2. Europe (U.K., Germany & Rest of Europe)
2.3. Asia Pacific (China, Japan, and Rest of APAC)
2.4. Latin America (Brazil, Mexico and Rest of LATAM)
2.5. Middle East and Africa (UAE, Saudi Arabia, South Africa)
2.2. Europe (U.K., Germany & Rest of Europe)
2.3. Asia Pacific (China, Japan, and Rest of APAC)
2.4. Latin America (Brazil, Mexico and Rest of LATAM)
2.5. Middle East and Africa (UAE, Saudi Arabia, South Africa)
3. Profiles
3.1. Abbott Laboratories
3.2. Amgen Inc.
3.3. Bayer AG
3.4. Bristol Myers Squibb Company
3.5. Eli Lilly and Company
3.6. F. Hoffmann-La Roche AG
3.7. GlaxoSmithKline Plc
3.8. Genentech Inc.
3.9. Merck & Co.
3.10. Johnson & Johnson Limited
3.11. Others
3.2. Amgen Inc.
3.3. Bayer AG
3.4. Bristol Myers Squibb Company
3.5. Eli Lilly and Company
3.6. F. Hoffmann-La Roche AG
3.7. GlaxoSmithKline Plc
3.8. Genentech Inc.
3.9. Merck & Co.
3.10. Johnson & Johnson Limited
3.11. Others
Download Free Request Sample : http://www.briskinsights.com/sample-request/608
For Blog:
About Us :
Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.
Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.
Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.
Contact Us :
Jennifer Smith
Office 1094
109 Vernon House
Friar Lane
Nottingham
NG1 6DQ
United Kingdom
Phone : +448081890034 (UK)
Email : sales@briskinsights.com
Website : http://www.briskinsights.com/
Office 1094
109 Vernon House
Friar Lane
Nottingham
NG1 6DQ
United Kingdom
Phone : +448081890034 (UK)
Email : sales@briskinsights.com
Website : http://www.briskinsights.com/
Comments
Post a Comment